may delay onset of psychosis
For young people who clearly seem to be developing early signs of schizophrenia, treatment with the anti-psychotic drug olanzapine appears to lower or delay the rate of conversion to full-blown psychosis, according to an article by a School of Medicine researcher in the May issue of The American Journal of Psychiatry.
The findings are preliminary, since 60 patients began the study and 17 completed it. Despite the long recruitment period and multiple study sites, participation was limited by the low incidence of pre-psychotic, or "prodromal," symptoms in the general population.
Schizophrenia affects about 1% of the population, or three million people, and is one of the most disabling medical disorders.
"Delay of the onset of the most severe symptoms of schizophrenia appears to have occurred because of the early recognition and treatment of these persons," says Dr. Robert Freedman, editor-in-chief of The American Journal of Psychiatry. "This enabled them to be better connected with treatment and to cope better with this devastating illness."
The study, "The Prevention Through Risk Identification, Management and Education (PRIME)," was conducted in two U.S. cities and two Canadian cities during 1998-2003. Senior author of the study was Dr. Thomas McGlashan, professor in Yale's Department of Psychiatry.
The participants were mostly adolescents. The individuals or their parents sought treatment because the adolescents had symptoms resembling those of psychosis, but less severe, including occasional periods of persecutory thoughts, abnormal sensory experiences such as hearing unusual sounds, and brief periods of incoherent thoughts, among other symptoms. Earlier studies suggest that many of these individuals would eventually develop the full symptoms of schizophrenia -- persistent paranoia, auditory hallucinations and disability.
The participants were randomly assigned for one year to olanzapine, a drug often used to treat schizophrenia, or a placebo, and then were observed for an additional year after treatment was stopped.
During the year of treatment the olanzapine group had greater improvement in prodromal symptoms with conversion to full psychosis in 16% of the olanzapine patients and 38% of the placebo patients. In the following year, after the treatment was discontinued, the rates of conversion to psychosis did not differ, and symptoms increased for the patients previously treated with olanzapine.
Research into the early detection and treatment of schizophrenia is considered important in determining whether psychosis and/or some of its disabilities can be prevented. Recent investigations have examined whether a long duration of untreated psychosis leads to a poorer outcome after treatment begins. Clinical trials to determine whether schizophrenia can be delayed or prevented are now possible due to improvements in anti-psychotic medications and in identification of high-risk individuals.
Weight gain is a frequent side-effect of olanzapine, although it does not cause body tremors as did the first generation of anti-psychotic medications. The patients in the PRIME study who took olanzapine gained an average of 19 pounds. Increases in glucose and cholesterol levels are also common in patients taking anti-psychotic medications, but the patients in this study did not develop these symptoms.
Eli Lilly Company and the National Institute of Mental Health funded the study.
-- By Jacqueline Weaver
T H I S
W E E K ' SS T O R I E S
Scientists identify new genus of monkey; first in 83 years
Divinity Dean reappointed to second term
Yale to celebrate 305th Commencement
Student photographs 'hidden beauty in everyday life'
Summertime at Yale
Brownell cited as one of world's '100 most influential people'
President Levin honored for increasing town-gown partnerships
ENDOWED PROFESSORSHIPS
David Bromwich appointed Sterling Professor of English
David Louis Quint named Sterling Professor of Comparative Literature
Brown-Dean is appointed Peter Strauss Family Assistant Professor
Four individuals will bring their expertise . . . to SOM
Two noted violinists . . . join the faculty of the School of Music
Three residential college masters named to second term
Laura Cruickshank named to post of University planner
Exhibit features English silver pieces once owned by tsars
Exhibits look back at 40 years of chiming bells and more
Major renovation effort begins at Cross Campus Librar
MEDICAL SCHOOL NEWS
Study confirms usefulness of naltrexone . . .
Treatment preferences for end-of-life care change with time . . .
Research shows medication may delay onset of psychosis
Claus will study genetics of breast cancer with Komen Foundation grant
Eight graduating seniors are bound for China as teaching fellows
IN MEMORIAM
Albert J. Reiss Jr., work led to reforms in policing
Dr. Norman Siegel, a world-renowned specialist on kidney disease . . .
Jaroslav Pelikan, noted scholar of Christianity, dies
Memorial service for William Sloan Coffin to be held May 27
Yale's nurse-midwives celebrate 50 years of community care
Talk will focus on life extension and human right
'Keepers of the Dream' to look at advancing urban education
Sociologist Adams honored for book on 'The Familial State'
Association honors Yale-affiliated scientists and engineers . . .
Journal of Industrial Ecology marks two milestones . . .
Grant will fund research on how human speech is shaped
'Trouble in Tahiti' to be performed during School of Music alumni weekend
Campaign invites community to 'Plant a Row for the Hungry'
Campus Notes
Bulletin Home|Visiting on Campus|Calendar of Events|In the News
Bulletin Board|Classified Ads|Search Archives|Deadlines
Bulletin Staff|Public Affairs|News Releases|
E-Mail Us|Yale Home